A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

September 28, 2023

Study Completion Date

October 12, 2023

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

GW117 Tablets

GW117 Tablets 20mg orally once a day

DRUG

GW117 Tablets

GW117 Tablets 20mg\*2 orally once a day

DRUG

GW117 Tablets

GW117 Tablets 20mg\*3 orally once a day

DRUG

Placebo

placebo orally once a day

Trial Locations (17)

Unknown

Hebei Mental Health Center, Baoding

Beijing Huilongguan Hospital, Beijing

Capital Medical University Affliated Anding HospitalContact, Beijing

Peking University Sixth Hospital, Beijing

Chengdu No.4 People's Hospital, Chengdu

Chongqing Mental Health Center, Chongqing

The third hospital of Daqing, Daqing

Huzhou Third People's Hospital, Huzhou

Jilin Neuropsychiatric Hospital, Jilin

The Third People's Hospital of Mianyang City, Mianyang

Shanghai Mental Health Center, Shanghai

Shenzhen Kangning Hospital, Shenzhen

The First Hospital of Hebei Medical University, Shijiazhuang

Tianjin Anding Hospital, Tianjin

Wuxi Mental Health Center, Wuxi

Xijing Hospital, the Fourth Military Medical University, Xi'an, China, Xi'an

Zhumadian Second People's Hospital, Zhumadian

All Listed Sponsors
lead

Beijing Greatway Pharmaceutical Technology Co.,Ltd.

INDUSTRY

NCT06796868 - A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder | Biotech Hunter | Biotech Hunter